Histological and CD31 Immunolocalization after Pulp Therapy using Mta or Portland Cement
Journal: International Journal of Dentistry and Oral Science (IJDOS) (Vol.05, No. 03)Publication Date: 2018-03-14
Authors : Lourenco-Neto N Marques NCT Prado MTO Vitor LLR Rodini CO Machado MAAM Oliveira TM;
Page : 622-625
Keywords : Dental Pulp; Immunohistochemistry; PECAM-1; Tooth Deciduous.;
Abstract
In cases of deep caries or trauma of primary teeth, pulpotomy is the procedure of choice to preserve pulp vitality and the teeth. This study aimed to evaluate the histological analysis and CD31 immunolocalization after pulpotomy using Mineral Trioxide Aggregate or Portland cement in human primary teeth. Twenty mandibular primary molars were divided into two study groups: G1 - Mineral Trioxide Aggregate and G2 - Portland cement. After conventional pulpotomy, clinical and radiographic follow-up, teeth at the regular exfoliation period were extracted for histological analysis and CD31 immunolocalization. The statistical analyses were performed by Kruskal-Wallis followed by Dunn test (P < 0.05). No statistically difference regarding inflammation and blood vessels amount (P > 0.05) were found between groups. The immunohistochemistry analysis revealed positive CD31 expression in the blood vessels of both studied groups. Group 1 showed mainly small blood vessels, while Group 2 exhibited larger blood vessels spread throughout the remaining pulp tissue not related to inflammatory infiltrate. Both materials behaved histologically similar regarding pulp inflammation and vascularization with intense CD31 positivity on the wall of blood vessels.
Other Latest Articles
- Main Considerations On The Implants In Previous Region: A Review
- The Detection of Serum and Urine Levels of Alpha 2-Macroglobulin in Nasopharyngeal Carcinoma Patients Receiving Late Period Radiotherapy and its Significance
- Sensory Evaluation of Gamma Irradiated Shrimp (Penaeus notialis) from Three Different Water Sources in Ghana
- Vision Loss Case of Bardet Biedl Syndrome
- Real Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration: A Subgroup Analysis of Pooled Retrospective RE-ENACT Study
Last modified: 2018-04-28 12:44:58